IU Licenses Breast Cancer Biomarker to Clarient | GenomeWeb

NEW YORK (GenomeWeb News) – Indiana University has licensed a breast cancer biomarker that researchers at the school have discovered to Clarient for development as a pharmacogenomic assay, the school said today.

According to IU, patients who test positive for the biomarker — FOXA1 — are more likely to respond to anti-estrogen hormone therapies, such as tamoxifen. The university said that in two studies involving around 675 patients, those who tested positive for the presence of FOXA1 had cancer considered less aggressive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.